| Monogram Health Professional Services Of Colorado, Pc | |
|
8354 E Northfield Blvd Ste 3700 Denver CO 80238-3131 | |
| (615) 673-4455 | |
| Not Available |
| Full Name | Monogram Health Professional Services Of Colorado, Pc |
|---|---|
| Speciality | Internal Medicine |
| Location | 8354 E Northfield Blvd Ste 3700, Denver, Colorado |
| Authorized Official Name and Position | Shawn L Verner (GENERAL COUNSEL & SECRETARY) |
| Authorized Official Contact | 6159941889 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Monogram Health Professional Services Of Colorado, Pc 5410 Maryland Way Ste 301 Brentwood TN 37027-5339 Ph: (615) 673-4455 | Monogram Health Professional Services Of Colorado, Pc 8354 E Northfield Blvd Ste 3700 Denver CO 80238-3131 Ph: (615) 673-4455 |
| NPI Number | 1023733359 |
|---|---|
| Provider Enumeration Date | 10/10/2022 |
| Last Update Date | 11/01/2022 |
| Medicare PECOS PAC ID | 6507239514 |
|---|---|
| Medicare Enrollment ID | O20230222000853 |
News Archive
Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.
Researchers at the Smidt Heart Institute at Cedars-Sinai discovered that a non-treatable form of lethal heart rhythm responsible for sudden cardiac arrest is twice as likely to be found in patients with the most common form of heart failure-heart failure with preserved ejection fraction (HFpEF), compared to heart failure with reduced ejection fraction (HFrEF).
Avid Radiopharmaceuticals, Inc. and PETNET Solutions, Inc., a wholly-owned subsidiary of Siemens Medical Solutions, USA, Inc., marked the first dose shipped from a PETNET Solutions manufacturing facility as part of its collaboration with Avid on Florbetapir F 18 (18F-AV-45 or Florbetapir), Avid's molecular imaging agent for positron emission tomography (PET) imaging of β-amyloid deposits in the brain, a key pathological component of Alzheimer's disease.
Six late-breaking clinical trials have been accepted for presentation next week during the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition in Denver, CO. These trials were selected based upon their potential impact to the field of nephrology.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023733359 | NPI | - | NPPES |
| Provider Name | Mindy Banks |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1679765309 PECOS PAC ID: 4587880844 Enrollment ID: I20140722001092 |
News Archive
Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.
Researchers at the Smidt Heart Institute at Cedars-Sinai discovered that a non-treatable form of lethal heart rhythm responsible for sudden cardiac arrest is twice as likely to be found in patients with the most common form of heart failure-heart failure with preserved ejection fraction (HFpEF), compared to heart failure with reduced ejection fraction (HFrEF).
Avid Radiopharmaceuticals, Inc. and PETNET Solutions, Inc., a wholly-owned subsidiary of Siemens Medical Solutions, USA, Inc., marked the first dose shipped from a PETNET Solutions manufacturing facility as part of its collaboration with Avid on Florbetapir F 18 (18F-AV-45 or Florbetapir), Avid's molecular imaging agent for positron emission tomography (PET) imaging of β-amyloid deposits in the brain, a key pathological component of Alzheimer's disease.
Six late-breaking clinical trials have been accepted for presentation next week during the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition in Denver, CO. These trials were selected based upon their potential impact to the field of nephrology.
› Verified 1 days ago
| Provider Name | Carrie Rebecca Hyde |
|---|---|
| Provider Type | Practitioner - Hospice/palliative Care |
| Provider Identifiers | NPI Number: 1114260726 PECOS PAC ID: 1658696307 Enrollment ID: I20230222001698 |
News Archive
Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.
Researchers at the Smidt Heart Institute at Cedars-Sinai discovered that a non-treatable form of lethal heart rhythm responsible for sudden cardiac arrest is twice as likely to be found in patients with the most common form of heart failure-heart failure with preserved ejection fraction (HFpEF), compared to heart failure with reduced ejection fraction (HFrEF).
Avid Radiopharmaceuticals, Inc. and PETNET Solutions, Inc., a wholly-owned subsidiary of Siemens Medical Solutions, USA, Inc., marked the first dose shipped from a PETNET Solutions manufacturing facility as part of its collaboration with Avid on Florbetapir F 18 (18F-AV-45 or Florbetapir), Avid's molecular imaging agent for positron emission tomography (PET) imaging of β-amyloid deposits in the brain, a key pathological component of Alzheimer's disease.
Six late-breaking clinical trials have been accepted for presentation next week during the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition in Denver, CO. These trials were selected based upon their potential impact to the field of nephrology.
› Verified 1 days ago
| Provider Name | Roshan Rajani |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1336494145 PECOS PAC ID: 2567785694 Enrollment ID: I20230405000015 |
News Archive
Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.
Researchers at the Smidt Heart Institute at Cedars-Sinai discovered that a non-treatable form of lethal heart rhythm responsible for sudden cardiac arrest is twice as likely to be found in patients with the most common form of heart failure-heart failure with preserved ejection fraction (HFpEF), compared to heart failure with reduced ejection fraction (HFrEF).
Avid Radiopharmaceuticals, Inc. and PETNET Solutions, Inc., a wholly-owned subsidiary of Siemens Medical Solutions, USA, Inc., marked the first dose shipped from a PETNET Solutions manufacturing facility as part of its collaboration with Avid on Florbetapir F 18 (18F-AV-45 or Florbetapir), Avid's molecular imaging agent for positron emission tomography (PET) imaging of β-amyloid deposits in the brain, a key pathological component of Alzheimer's disease.
Six late-breaking clinical trials have been accepted for presentation next week during the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition in Denver, CO. These trials were selected based upon their potential impact to the field of nephrology.
› Verified 1 days ago
| Provider Name | Hilda Ana Deen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1538778543 PECOS PAC ID: 5294145652 Enrollment ID: I20231117001293 |
News Archive
Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.
Researchers at the Smidt Heart Institute at Cedars-Sinai discovered that a non-treatable form of lethal heart rhythm responsible for sudden cardiac arrest is twice as likely to be found in patients with the most common form of heart failure-heart failure with preserved ejection fraction (HFpEF), compared to heart failure with reduced ejection fraction (HFrEF).
Avid Radiopharmaceuticals, Inc. and PETNET Solutions, Inc., a wholly-owned subsidiary of Siemens Medical Solutions, USA, Inc., marked the first dose shipped from a PETNET Solutions manufacturing facility as part of its collaboration with Avid on Florbetapir F 18 (18F-AV-45 or Florbetapir), Avid's molecular imaging agent for positron emission tomography (PET) imaging of β-amyloid deposits in the brain, a key pathological component of Alzheimer's disease.
Six late-breaking clinical trials have been accepted for presentation next week during the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition in Denver, CO. These trials were selected based upon their potential impact to the field of nephrology.
› Verified 1 days ago
| Provider Name | Monica Escobedo |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336779081 PECOS PAC ID: 0345647574 Enrollment ID: I20240105004232 |
News Archive
Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.
Researchers at the Smidt Heart Institute at Cedars-Sinai discovered that a non-treatable form of lethal heart rhythm responsible for sudden cardiac arrest is twice as likely to be found in patients with the most common form of heart failure-heart failure with preserved ejection fraction (HFpEF), compared to heart failure with reduced ejection fraction (HFrEF).
Avid Radiopharmaceuticals, Inc. and PETNET Solutions, Inc., a wholly-owned subsidiary of Siemens Medical Solutions, USA, Inc., marked the first dose shipped from a PETNET Solutions manufacturing facility as part of its collaboration with Avid on Florbetapir F 18 (18F-AV-45 or Florbetapir), Avid's molecular imaging agent for positron emission tomography (PET) imaging of β-amyloid deposits in the brain, a key pathological component of Alzheimer's disease.
Six late-breaking clinical trials have been accepted for presentation next week during the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition in Denver, CO. These trials were selected based upon their potential impact to the field of nephrology.
› Verified 1 days ago
| Provider Name | Sarah Louise Bivens |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386653251 PECOS PAC ID: 7911067079 Enrollment ID: I20240131001684 |
News Archive
Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.
Researchers at the Smidt Heart Institute at Cedars-Sinai discovered that a non-treatable form of lethal heart rhythm responsible for sudden cardiac arrest is twice as likely to be found in patients with the most common form of heart failure-heart failure with preserved ejection fraction (HFpEF), compared to heart failure with reduced ejection fraction (HFrEF).
Avid Radiopharmaceuticals, Inc. and PETNET Solutions, Inc., a wholly-owned subsidiary of Siemens Medical Solutions, USA, Inc., marked the first dose shipped from a PETNET Solutions manufacturing facility as part of its collaboration with Avid on Florbetapir F 18 (18F-AV-45 or Florbetapir), Avid's molecular imaging agent for positron emission tomography (PET) imaging of β-amyloid deposits in the brain, a key pathological component of Alzheimer's disease.
Six late-breaking clinical trials have been accepted for presentation next week during the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition in Denver, CO. These trials were selected based upon their potential impact to the field of nephrology.
› Verified 1 days ago
| Provider Name | Sabina Sandhu |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1679990659 PECOS PAC ID: 1052611563 Enrollment ID: I20240221000067 |
News Archive
Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.
Researchers at the Smidt Heart Institute at Cedars-Sinai discovered that a non-treatable form of lethal heart rhythm responsible for sudden cardiac arrest is twice as likely to be found in patients with the most common form of heart failure-heart failure with preserved ejection fraction (HFpEF), compared to heart failure with reduced ejection fraction (HFrEF).
Avid Radiopharmaceuticals, Inc. and PETNET Solutions, Inc., a wholly-owned subsidiary of Siemens Medical Solutions, USA, Inc., marked the first dose shipped from a PETNET Solutions manufacturing facility as part of its collaboration with Avid on Florbetapir F 18 (18F-AV-45 or Florbetapir), Avid's molecular imaging agent for positron emission tomography (PET) imaging of β-amyloid deposits in the brain, a key pathological component of Alzheimer's disease.
Six late-breaking clinical trials have been accepted for presentation next week during the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition in Denver, CO. These trials were selected based upon their potential impact to the field of nephrology.
› Verified 1 days ago
News Archive
Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration has approved the brand name VELETRI® for the company's epoprostenol for injection therapy. VELETRI has been commercially available since April 2010 as Epoprostenol for Injection for the treatment of moderate to severe pulmonary arterial hypertension (PAH) and PAH associated with the scleroderma spectrum of disease. Actelion plans to release VELETRI-labeled product by early fourth quarter of 2010.
Researchers at the Smidt Heart Institute at Cedars-Sinai discovered that a non-treatable form of lethal heart rhythm responsible for sudden cardiac arrest is twice as likely to be found in patients with the most common form of heart failure-heart failure with preserved ejection fraction (HFpEF), compared to heart failure with reduced ejection fraction (HFrEF).
Avid Radiopharmaceuticals, Inc. and PETNET Solutions, Inc., a wholly-owned subsidiary of Siemens Medical Solutions, USA, Inc., marked the first dose shipped from a PETNET Solutions manufacturing facility as part of its collaboration with Avid on Florbetapir F 18 (18F-AV-45 or Florbetapir), Avid's molecular imaging agent for positron emission tomography (PET) imaging of β-amyloid deposits in the brain, a key pathological component of Alzheimer's disease.
Six late-breaking clinical trials have been accepted for presentation next week during the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition in Denver, CO. These trials were selected based upon their potential impact to the field of nephrology.
› Verified 1 days ago
Family Dentistry Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 7701 E 1st Pl Ste B, Denver, CO 80230 Phone: 303-399-4444 Fax: 303-355-6855 | |
Care Connections Of Illinois, P.c. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1600 Stout St Ste 2000, Denver, CO 80202 Phone: 720-204-5760 | |
Denver Occupational & Aviation Med. Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3700 Havana St, Suite 200, Denver, CO 80239 Phone: 303-373-4456 Fax: 303-373-4501 | |
Dr. D. J. Strickland, Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9669 Huron St Ste 202, Denver, CO 80260 Phone: 303-428-7509 Fax: 303-429-0032 | |
Dh Southwest Clinic Laboratory Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1339 S Federal Blvd, Denver, CO 80219 Phone: 303-602-0000 Fax: 303-602-0500 | |
Mile High Council On Alcoholism And Drug Abuse Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4242 Delaware St, Denver, CO 80216 Phone: 303-825-8113 | |
Direct Diabetes Consultants Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1700 Bassett Apt 1603, Denver, CO 80202 Phone: 720-739-0734 |